Analytical Data
-
Gene name
CDR2
- Application
-
Alternative Names
CDR2；PCD17；Cerebellar degeneration-related Protein 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q01850
-
Expression Region
1-454aa
-
AA Sequence
MLAENLVEEFEMKEDEPWYDHQDLQQDLQLAAELGKTLLDRNTELEDSVQ QMYTTNQEQLQEIEYLTKQVELLRQMNEQHAKVYEQLDVTARELEETNQK LVADSKASQQKILSLTETIECLQTNIDHLQSQVEELKSSGQGRRSPGKCD QEKPAPSFACLKELYDLRQHFVYDHVFAEKITSLQGQPSPDEEENEHLKK TVTMLQAQLSLERQKRVTMEEEYGLVLKENSELEQQLGATGAYRARALEL EAEVAEMRQMLQSEHPFVNGVEKLVPDSLYVPFKEPSQSLLEEMFLTVPE SHRKPLKRSSSETILSSLAGSDIVKGHEETCIRRAKAVKQRGISLLHEVD TQYSALKVKYEELLKKCQEEQDSLSHKAVQTSRAAAKDLTGVNAQSEPVA SGWELASVNPEPVSSPTTPPEYKALFKEIFSCIKKTKQEIDEQRTKYRSL SSHS
-
Molecular Weight
56 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDR2, or cancer drug resistance 2, is a protein that has garnered increasing attention in the field of cancer research due to its role in mediating resistance to chemotherapeutic agents. Understanding the mechanisms by which CDR2 contributes to drug resistance is crucial for improving treatment outcomes in cancer patients, as many tumors exhibit a tendency to develop resistance to available therapies, leading to treatment failure. Previous studies have indicated that CDR2 may influence cell survival and proliferation in response to various stressors, including drug treatment. Moreover, its expression levels have been correlated with poor prognosis in several cancer types, highlighting its potential as a biomarker for treatment response. Researchers are investigating the molecular pathways involving CDR2 to elucidate its function and interactions within cancer cells. These efforts aim to identify targeted therapeutic strategies that can overcome drug resistance mediated by CDR2, thereby enhancing the efficacy of existing treatments and potentially improving patient survival rates. The ongoing exploration of CDR2’s role in cancer biology promises to shed light on novel approaches for combating drug resistance and tailoring more effective therapies for individuals facing this challenge.
